SCHEMBL20120950

SCHEMBL20120950

COC(=O)C=Cc1ccc(N2CCN(C(=O)OC(C)(C)C)C(I)C2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.45
MAP4K4 O95819 1/20 0.41
RET P07949 2/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
GPR119 Q8TDV5 3/20 0.37
ABCB1 P08183 1/20 0.37
FDPS P14324 1/20 0.36
NR1H2 P55055 2/20 0.35
NR1H3 Q13133 2/20 0.35
KDM1A O60341 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DPP4 P27487 1/20 0.35
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20214374 0.83 GPR119 (0.52) MAP4K4RETDDB1CRBNGPR119
SCHEMBL20128887 0.83 GPR119 (0.52) MAP4K4RETDDB1CRBNGPR119
SCHEMBL22579215 0.76 CKS1B (0.50) RETDDB1CRBNGPR119ABCB1
SCHEMBL4622159 0.73 CA12 (0.47) FDPSKDM4EKMT2ASMN1; SMN2CA12
SCHEMBL10317402 0.73 SMN1; SMN2 (0.54) MAP4K4RETDDB1CRBNGPR119
SCHEMBL10317400 0.73 SMN1; SMN2 (0.54) MAP4K4RETDDB1CRBNGPR119
SCHEMBL29547544 0.73 NPSR1 (0.46) FDPSKDM4EKMT2ASMN1; SMN2CA12
SCHEMBL19088637 0.73 FGFR2 (0.44) FDPSKDM4EKMT2ASMN1; SMN2CA12
SCHEMBL3784306 0.72 ALDH1A1 (0.49) KDM4EKMT2ASMN1; SMN2CA12CA1
SCHEMBL3784304 0.72 ALDH1A1 (0.49) KDM4EKMT2ASMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 US disclosed
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-23 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 HDAC1 1821/4885MAP4K4 2799/4885RET 305/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 HDAC1 1821/4885MAP4K4 2799/4885RET 305/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT HDAC1 2352/4885MAP4K4 2913/4885RET 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.